JMP reiterates Indevus at strong buy

Indevus Pharmaceuticals, Inc. was reiterated at a strong buy by JMP Securities analyst Adam Cutler after the company filed a New Drug Application with the Food and Drug Administration for Sanctura XR, the once-daily formulation of Sanctura currently marketed for overactive bladder. Cutler believes that Sanctura XR will be approved and launched in the second half of 2007. Shares of the Lexington, Mass.-based biopharmaceutical company were up 12 cents, or 1.98%, at $6.19. (Nasdaq: IDEV)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.